Clinuvel Pharmaceuticals Limited
Recent
price
P/E
ratio
div
yld
0.67%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Clinuvel Pharmaceuticals Limited specializes in the development and commercialization of therapies for patients with severe genetic and skin disorders. Its core products and services focus on photoprotection and treatment of conditions caused by photosensitivity, including the FDA-approved drug Scenesse (afamelanotide), which is used to prevent phototoxic reactions in patients with erythropoietic protoporphyria (EPP). The company also develops therapies for other skin disorders and leverage melanocortin-based treatments for rare diseases. Clinuvel operates globally, with a headquarters in Melbourne, Australia, and a presence in Europe, the United States, and Asia. Founded in 1999, Clinuvel Pharmaceuticals has recently made strategic expansions by initiating new clinical programs targeting additional indications such as vitiligo and other photosensitive conditions. The company has formed key partnerships to advance its research pipeline and broaden its market reach. It has also enhanced its manufacturing and distribution capabilities to support global commercialization efforts. These developments reflect Clinuvel’s commitment to expanding its therapeutic portfolio beyond its flagship product while maintaining a focus on rare and underserved patient populations. The company remains publicly traded on the Australian Securities Exchange under the ticker CUV.AX. This combination of specialized products, ongoing innovation, and strategic growth initiatives positions Clinuvel as a prominent player in the pharmaceutical biotech sector dedicated to photomedicine and rare diseases.
Company News
A decade of profitability provides foundation for CLINUVEL's U.S. expansion
CLINUVEL implements strategic reorganisation to refocus on U.S. markets
CLINUVEL's ADS to commence trading on Nasdaq
SCENESSE® approved for EPP in Canada
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2026 Earnings Call Transcript
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
Clinuvel Pharmaceuticals Limited (CLVLY) Shareholder/Analyst Call Transcript
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
Clinuvel Pharmaceuticals Limited (CLVLY) Q4 2025 Earnings Call Transcript
CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
Clinuvel Introduces Groundbreaking Vitiligo Program at the World's Biggest Dermatology Meeting, AAD 2025
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2025 Earnings Call Transcript
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
Afamelanotide in fair-skinned Parkinson's patients
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
Malibu shines a light on CLINUVEL's pioneering work in photomedicine
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript